CEPH - CEPHALON Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH - CEPHALON

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jon Khymn who started this subject	9/27/2002 1:24:49 PM
From: Doc Bones	Read Replies (1) of 109

13:10 ET CEPH Cephalon hit by Waksal rumors (39.52 -1.88) Stock sees steep decline in recent action with heavy options activity; we're hearing trading floor rumors that Imclone's (IMCL) CEO Sam Waksal might seek a plea bargain in which he would testify that he shared the FDA/Erbitux information with CEPH's CEO before it was made public. It is impossible to confirm the veracity of this rumor, and it is not even known if CEPH's CEO owned any IMCL shares or took any action whatsoever prior to the FDA news on Erbitux, but this talk does appear to be hitting the stock. [briefing.com] ----- Rather odd rumor. Stock has made small bounce shortly after. Doc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next